SK286365B6 - Voľná lieková partikulárna forma, farmaceutická kompozícia s jej obsahom, jej použitie a spôsob jejvýroby - Google Patents

Voľná lieková partikulárna forma, farmaceutická kompozícia s jej obsahom, jej použitie a spôsob jejvýroby Download PDF

Info

Publication number
SK286365B6
SK286365B6 SK172-2002A SK1722002A SK286365B6 SK 286365 B6 SK286365 B6 SK 286365B6 SK 1722002 A SK1722002 A SK 1722002A SK 286365 B6 SK286365 B6 SK 286365B6
Authority
SK
Slovakia
Prior art keywords
compound
particles
free
particulate form
free drug
Prior art date
Application number
SK172-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK1722002A3 (en
Inventor
Neil R. Anderson
Kerry J. Hartauer
Martha A. Kral
Gregory A. Stephenson
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22520112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286365(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of SK1722002A3 publication Critical patent/SK1722002A3/sk
Publication of SK286365B6 publication Critical patent/SK286365B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
SK172-2002A 1999-08-03 2000-08-01 Voľná lieková partikulárna forma, farmaceutická kompozícia s jej obsahom, jej použitie a spôsob jejvýroby SK286365B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14704899P 1999-08-03 1999-08-03
PCT/US2000/020981 WO2001008688A2 (en) 1999-08-03 2000-08-01 Beta-carboline drug products

Publications (2)

Publication Number Publication Date
SK1722002A3 SK1722002A3 (en) 2002-05-09
SK286365B6 true SK286365B6 (sk) 2008-08-05

Family

ID=22520112

Family Applications (1)

Application Number Title Priority Date Filing Date
SK172-2002A SK286365B6 (sk) 1999-08-03 2000-08-01 Voľná lieková partikulárna forma, farmaceutická kompozícia s jej obsahom, jej použitie a spôsob jejvýroby

Country Status (33)

Country Link
EP (1) EP1200092B1 (pl)
JP (1) JP4456788B2 (pl)
KR (1) KR20020063842A (pl)
CN (2) CN1377270A (pl)
AR (1) AR033953A1 (pl)
AT (1) ATE264680T1 (pl)
AU (1) AU773666B2 (pl)
BR (1) BR0012901A (pl)
CA (1) CA2380087C (pl)
CO (1) CO5200849A1 (pl)
CZ (1) CZ300151B6 (pl)
DE (1) DE60010089T2 (pl)
DK (1) DK1200092T3 (pl)
DZ (1) DZ3180A1 (pl)
EA (1) EA004302B9 (pl)
ES (1) ES2220506T3 (pl)
HK (1) HK1044278B (pl)
HR (1) HRP20020091B1 (pl)
HU (1) HU229443B1 (pl)
IL (1) IL147642A0 (pl)
MX (1) MXPA02001197A (pl)
MY (1) MY125428A (pl)
NO (1) NO321602B1 (pl)
NZ (1) NZ516613A (pl)
PE (1) PE20010480A1 (pl)
PL (1) PL199469B1 (pl)
PT (1) PT1200092E (pl)
SK (1) SK286365B6 (pl)
SV (1) SV2002000137A (pl)
TW (1) TWI235658B (pl)
UA (1) UA71629C2 (pl)
WO (1) WO2001008688A2 (pl)
ZA (1) ZA200200825B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1200090B1 (en) * 1999-08-03 2013-09-11 ICOS Corporation Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction
US8063214B2 (en) * 2004-10-28 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of tadalafil
US8865722B2 (en) 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
WO2012085927A2 (en) * 2010-12-02 2012-06-28 Mylan Laboratories, Limited Tadalafil compositions
WO2012095151A1 (en) 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
JP5930686B2 (ja) * 2011-12-07 2016-06-08 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
EP2826079B1 (de) 2012-03-15 2021-01-20 Merck Patent GmbH Elektronische vorrichtungen
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
CN105310984A (zh) * 2014-06-10 2016-02-10 合肥贝霓医药科技有限公司 一种pde5抑制剂的超微粉体及其制备方法
PL3111929T3 (pl) * 2014-06-24 2019-01-31 Wooshin Labottach Co., Ltd. Ulegający rozpadowi w jamie ustnej preparat w postaci błony zawierający tadalafil i sposób jego wytwarzania
SI3466951T1 (sl) 2014-07-23 2022-05-31 Krka, D.D., Novo Mesto Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila
JP2016106139A (ja) * 2016-03-07 2016-06-16 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
AU2018397436A1 (en) * 2017-12-26 2020-08-13 Ftf Pharma Private Limited Liquid oral formulations for PDE V inhibitors
ES2824818T3 (es) 2018-01-10 2021-05-13 Gap S A Cápsulas de gelatina blanda que comprenden una suspensión de tadalafilo
CN110638770B (zh) * 2019-10-25 2022-04-05 株洲千金药业股份有限公司 他达拉非片剂的制备方法及以该方法制得的片剂
WO2023227185A1 (en) * 2022-05-27 2023-11-30 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and nanomilling process for the preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions

Also Published As

Publication number Publication date
CZ300151B6 (cs) 2009-02-25
NZ516613A (en) 2003-08-29
SK1722002A3 (en) 2002-05-09
DZ3180A1 (fr) 2001-02-08
PL353268A1 (pl) 2003-11-03
CA2380087A1 (en) 2001-02-08
PL199469B1 (pl) 2008-09-30
NO321602B1 (no) 2006-06-12
DE60010089D1 (de) 2004-05-27
EA004302B9 (ru) 2019-01-31
HU229443B1 (en) 2013-12-30
MY125428A (en) 2006-07-31
AR033953A1 (es) 2004-01-21
NO20020531D0 (no) 2002-02-01
HUP0202781A2 (hu) 2002-12-28
HRP20020091A2 (en) 2004-02-29
EP1200092B1 (en) 2004-04-21
CO5200849A1 (es) 2002-09-27
HRP20020091B1 (en) 2006-02-28
HUP0202781A3 (en) 2003-10-28
SV2002000137A (es) 2002-06-07
EP1200092A2 (en) 2002-05-02
TWI235658B (en) 2005-07-11
UA71629C2 (en) 2004-12-15
AU6508400A (en) 2001-02-19
HK1044278B (zh) 2004-10-08
JP4456788B2 (ja) 2010-04-28
MXPA02001197A (es) 2003-02-12
ZA200200825B (en) 2003-04-30
CA2380087C (en) 2007-05-01
HK1044278A1 (en) 2002-10-18
KR20020063842A (ko) 2002-08-05
ES2220506T3 (es) 2004-12-16
IL147642A0 (en) 2002-08-14
NO20020531L (no) 2002-04-03
WO2001008688A3 (en) 2001-08-16
DE60010089T2 (de) 2004-10-14
PT1200092E (pt) 2004-07-30
WO2001008688A2 (en) 2001-02-08
CN1377270A (zh) 2002-10-30
EA200200119A1 (ru) 2002-06-27
DK1200092T3 (da) 2004-08-16
AU773666B2 (en) 2004-06-03
JP2003505510A (ja) 2003-02-12
CZ2002387A3 (cs) 2002-10-16
EA004302B1 (ru) 2004-02-26
CN101134019A (zh) 2008-03-05
PE20010480A1 (es) 2001-05-26
ATE264680T1 (de) 2004-05-15
BR0012901A (pt) 2002-04-16

Similar Documents

Publication Publication Date Title
US6821975B1 (en) Beta-carboline drug products
SK286365B6 (sk) Voľná lieková partikulárna forma, farmaceutická kompozícia s jej obsahom, jej použitie a spôsob jejvýroby
KR100738861B1 (ko) 베타-카르볼린 약학 조성물
AT11571U1 (de) Pharmazeutische dosierungsformen
KR20230149861A (ko) 아픽사반 제제
WO2005115346A9 (en) Pharmaceutical composition containing risperidone
Rekha et al. Formulation and development of Bilastine tablets 20 mg
Ellakwa et al. Enhancement of the solubility and the dissolution rate of oral nimodipine formulation with solid dispersion
US10085991B2 (en) Formulation inhibiting effects of low acid environment
EP4268802A1 (en) Vilazodone pharmaceutical composition, preparation method therefor and use thereof
KR100671714B1 (ko) 미분화된 펠로디핀 함유 지속 방출성 제제
Nithiyananthan et al. Formulation and evaluation of tamsulosin hydrochloride as sustained release matrix tablet
AU2012202717A1 (en) Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: ICOS CORPORATION, INDIANAPOLIS, IN, US

Free format text: FORMER OWNER: LILLY ICOS LLC, WILMINGTON, DE, US

Effective date: 20091214

MK4A Expiry of patent

Expiry date: 20200801